Mycophenolate mofetil initiation in renal transplant patients at different times posttransplantation: The TranCept switch study

Transplantation

Volumn 91, Issue 9, 2011, Pages 984-990

  Meier Kriesche, Herwig Ulf ^a   Merville, Pierre ^b   Tedesco Silva, Helio ^c   Heemann, Uwe ^d   Kes, Petar ^e   Haller, Hermann ^f   Rostaing, Lionel ^g   Gafner, Nesrin ^h   Bernasconi, Corrado ⁱ  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b HÔPITAL PELLEGRIN   (France)

^c HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e KBC Zagreb   (Croatia)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g CHU RANGUEIL   (France)

^h Nesrin Gafner Consulting   (Switzerland)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Calcineurin inhibitor withdrawal; Glomerular filtration rate; Mycophenolate mofetil; Nephrotoxicity

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHRONIC GRAFT REJECTION; DIETARY INTAKE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ADULT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 79955537315     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182130966     Document Type: Article

References (23)

1. Meyers CM, Kirk AD. Workshop on late renal allograft dysfunction. Am J Transplant 2005; 5: 1600.
2. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
3. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: Current concepts and future directions. Transplantation 2006; 81: 643.
4. Birnbaum LM, Lipman M, Paraskevas S, et al. Management of chronic allograft nephropathy: A systematic review. Clin J Am Soc Nephrol 2009; 4: 860.
5. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve longterm outcomes after renal transplantation.NEngl J Med 2002; 346: 580
6. Ekberg H. Calcineurin sparing in renal transplantation. Transplantation 2008; 86: 761.
7. Moore J, Middleton L, Cockwell P, et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: A systematic review and meta-analysis. Transplantation 2009; 87: 591.
8. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitorsparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1.
9. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant recipients. Am J Transplant 2009; 9(suppl 3): S1.
10. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111.
11. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Eng J Med 2007; 357: 2562.
12. Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003; 3: 68.
13. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752.
14. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405.
15. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655.
16. Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993; 91: 2144.
17. Curtis JJ, Dubovsky E, Whelchel JD, et al. Cyclosporine in therapeutic doses increases allograft vascular resistance. Lancet 1986; 2: 477.
18. Gonzalez Molina M, Seron D, Garcia del Moral R, et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004; 77: 215.
19. Frimat L, Cassuto-Viguier E, Charpentier B, et al. Impact of cyclosporine reduction with MMF: A randomized trial in chronic allograft dysfunction. The "Reference" study. Am J Transplant 2006; 6: 2725.
20. Dudley C, Pohanka E, Riad H, et al. Mycophenolate Mofetil Creeping Creatinine Study Group. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" study. Transplantation 2005; 79: 466.
21. Levey AS, Greene T, Kusek JW, et al.MDRDStudy Group. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 2000; 11: 155A.
22. Jones RH, Molitoris BA. A statistical method for determining the breakpoint of two lines. Anal Biochem 1984; 141: 287.
23. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria, R Foundation for Statistical Computing 2005